Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/24084Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Papaioannides, D. | en |
| dc.contributor.author | Bouropoulos, C. | en |
| dc.contributor.author | Sinapides, D. | en |
| dc.contributor.author | Korantzopoulos, P. | en |
| dc.contributor.author | Akritidis, N. | en |
| dc.date.accessioned | 2015-11-24T19:37:49Z | - |
| dc.date.available | 2015-11-24T19:37:49Z | - |
| dc.identifier.issn | 0301-1623 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/24084 | - |
| dc.rights | Default Licence | - |
| dc.subject | Acute Kidney Injury/*chemically induced | en |
| dc.subject | Aged | en |
| dc.subject | Cyclooxygenase 2 | en |
| dc.subject | Cyclooxygenase 2 Inhibitors | en |
| dc.subject | Cyclooxygenase Inhibitors/*adverse effects | en |
| dc.subject | Humans | en |
| dc.subject | Isoenzymes/*antagonists & inhibitors | en |
| dc.subject | Kidney/drug effects | en |
| dc.subject | Lactones/*adverse effects | en |
| dc.subject | Male | en |
| dc.subject | Membrane Proteins | en |
| dc.subject | Prostaglandin-Endoperoxide Synthases | en |
| dc.subject | Sulfones | en |
| dc.title | Acute renal dysfunction associated with selective COX-2 inhibitor therapy | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/12452607 | - |
| heal.identifier.secondary | http://www.springerlink.com/content/q0n2wq9332203066/fulltext.pdf | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2001 | - |
| heal.abstract | The recent release of the selective cyclooxygenase-2 (COX-2) enzyme inhibitors for the treatment of various inflammatory disorders and pain syndromes has been associated with a clear-cut decrease in adverse gastrointestinal effects. The nephrotoxic effect of selective COX-2 inhibitors has not yet been firmly established. We report a case of reversible acute renal failure due to rofecoxib treatment in an elderly patient with several risk factors associated with traditional nonselective nonsteroidal anti-inflammatory drug (NSAID)-related nephrotoxicity. It is prudent to approach therapy with selective COX-2 inhibitors cautiously and in a fashion similar to traditional NSAID therapy for patients with risk factors that induce prostaglandin-dependent renal function. | en |
| heal.journalName | Int Urol Nephrol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Papaioannides-2001-Acute renal dysfunct.pdf | 44.75 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
